BioCentury | Mar 17, 2003
Clinical News

Calanolide A: Phase I

...venture between the state government of Sarawak, Malaysia, and Advanced Life Sciences Inc (Woodridge, Ill.). Sarawak MediChem Pharmaceuticals Inc....
BioCentury | Jul 15, 2002
Clinical News

Calanolide A: Sarawak will begin in 3Q02 a U.S. Phase I trial of Calanolide A in 48 volunteers. Sarawak is a 50-50 joint venture between the state government of

Sarawak MediChem Pharmaceuticals Inc. , Lemont, Ill. Product: Calanolide A Business: Infectious diseases Therapeutic category: Viral replication Target: Reverse transcriptase Description: Naturally occurring non-nucleoside reverse transcriptase inhibitor (NNRTI) Indication: Treat HIV infection Endpoint: Safety, pharmacokinetics Status:...
BioCentury | Jun 25, 2001
Tools & Techniques

Surprise NNRTI finding

...market or in development include Boehringer Ingelheim Pharmaceuticals Inc. (Ridgefield, Conn.), DuPont Pharma (Wilmington, Del.), Sarawak MediChem Pharmaceuticals Inc....
BioCentury | Feb 7, 2000
Clinical News

: Phase Ib

...additional monotherapy trials prior to conducting Phase II studies in combination with other antiviral drugs. Sarawak MediChem Pharmaceuticals Inc....
BioCentury | Jul 19, 1999
Clinical News

(+)-calanolide A: Began Phase Ib study

Sarawak MediChem Pharmaceuticals Inc., Lemont, Ill. Product: (+)-calanolide A Business: Infectious diseases Therapeutic category: Viral replication Target: HIV reverse transcriptase Description: Non-nucleoside reverse transcriptase inhibitor (NNRTI) Indication: Treat HIV infection/AIDS Status: Sarawak, a joint venture...
BioCentury | Oct 5, 1998
Clinical News

Sarawak began U.S. Phase Ib testing of (+)-calanolide A

Sarawak MediChem Pharmaceuticals Inc., Lemont, Ill. Product: (+)-calanolide A non-nucleoside reverse transcriptase inhibitor (NNRTI) Indication: Treat HIV infection/AIDS Status: Sarawak began U.S. Phase Ib testing of (+)-calanolide A in 32 treatment-naive HIV-infected patients. The placebo-controlled...
BioCentury | Feb 9, 1998
Clinical News

Calanolide A naturally occurring non-nucleoside reverse transcriptase inhibitor data

...this summer. Data were presented at the Conference on Retroviruses and Opportunistic Infections in Chicago. Sarawak MediChem Pharmaceuticals Inc....
BioCentury | Jun 23, 1997
Clinical News

(+)-Calanolide A, non-nucleoside blocker of reverse transcriptase: Update

Sarawak MediChem Pharmaceuticals Inc., Lemont, Ill. Product: (+)-Calanolide A, non-nucleoside blocker of reverse transcriptase Indication: Treat AIDS Status: Sarawak last week began Phase Ia testing in 50 patients in a seven-month U.S. trial. A single...
BioCentury | Apr 28, 1997
Company News

MediChem Research Inc., State of Sarawak deal

...The parties formed Sarawak MediChem Pharmaceuticals Inc., a joint venture to advance clinical development of Calanolide A, an HIV...
Items per page:
1 - 9 of 9
BioCentury | Mar 17, 2003
Clinical News

Calanolide A: Phase I

...venture between the state government of Sarawak, Malaysia, and Advanced Life Sciences Inc (Woodridge, Ill.). Sarawak MediChem Pharmaceuticals Inc....
BioCentury | Jul 15, 2002
Clinical News

Calanolide A: Sarawak will begin in 3Q02 a U.S. Phase I trial of Calanolide A in 48 volunteers. Sarawak is a 50-50 joint venture between the state government of

Sarawak MediChem Pharmaceuticals Inc. , Lemont, Ill. Product: Calanolide A Business: Infectious diseases Therapeutic category: Viral replication Target: Reverse transcriptase Description: Naturally occurring non-nucleoside reverse transcriptase inhibitor (NNRTI) Indication: Treat HIV infection Endpoint: Safety, pharmacokinetics Status:...
BioCentury | Jun 25, 2001
Tools & Techniques

Surprise NNRTI finding

...market or in development include Boehringer Ingelheim Pharmaceuticals Inc. (Ridgefield, Conn.), DuPont Pharma (Wilmington, Del.), Sarawak MediChem Pharmaceuticals Inc....
BioCentury | Feb 7, 2000
Clinical News

: Phase Ib

...additional monotherapy trials prior to conducting Phase II studies in combination with other antiviral drugs. Sarawak MediChem Pharmaceuticals Inc....
BioCentury | Jul 19, 1999
Clinical News

(+)-calanolide A: Began Phase Ib study

Sarawak MediChem Pharmaceuticals Inc., Lemont, Ill. Product: (+)-calanolide A Business: Infectious diseases Therapeutic category: Viral replication Target: HIV reverse transcriptase Description: Non-nucleoside reverse transcriptase inhibitor (NNRTI) Indication: Treat HIV infection/AIDS Status: Sarawak, a joint venture...
BioCentury | Oct 5, 1998
Clinical News

Sarawak began U.S. Phase Ib testing of (+)-calanolide A

Sarawak MediChem Pharmaceuticals Inc., Lemont, Ill. Product: (+)-calanolide A non-nucleoside reverse transcriptase inhibitor (NNRTI) Indication: Treat HIV infection/AIDS Status: Sarawak began U.S. Phase Ib testing of (+)-calanolide A in 32 treatment-naive HIV-infected patients. The placebo-controlled...
BioCentury | Feb 9, 1998
Clinical News

Calanolide A naturally occurring non-nucleoside reverse transcriptase inhibitor data

...this summer. Data were presented at the Conference on Retroviruses and Opportunistic Infections in Chicago. Sarawak MediChem Pharmaceuticals Inc....
BioCentury | Jun 23, 1997
Clinical News

(+)-Calanolide A, non-nucleoside blocker of reverse transcriptase: Update

Sarawak MediChem Pharmaceuticals Inc., Lemont, Ill. Product: (+)-Calanolide A, non-nucleoside blocker of reverse transcriptase Indication: Treat AIDS Status: Sarawak last week began Phase Ia testing in 50 patients in a seven-month U.S. trial. A single...
BioCentury | Apr 28, 1997
Company News

MediChem Research Inc., State of Sarawak deal

...The parties formed Sarawak MediChem Pharmaceuticals Inc., a joint venture to advance clinical development of Calanolide A, an HIV...
Items per page:
1 - 9 of 9